Benjamin van Leeuwen, MD
Psychiatry · Layton, UTNPI 1942734785
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 364 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,912, more than ten times the $73 reported in 2019. Among psychiatry clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 364 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- AbbVie$1K
- Axsome Therapeutics, Inc.$570
- Neurocrine Biosciences, Inc.$476
- Otsuka America Pharmaceutical, Inc.$446
- Teva Pharmaceuticals USA, Inc.$398
- plus $2K from 26 others
What the payments were for
- Food & beverage$6,31698%
- Education$1372%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 67 | $1,134 |
| AbbVie | 79 | $1,128 |
| Axsome Therapeutics, Inc. | 33 | $570 |
| Neurocrine Biosciences, Inc. | 23 | $476 |
| Otsuka America Pharmaceutical, Inc. | 23 | $446 |
| Teva Pharmaceuticals USA, Inc. | 19 | $398 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $373 |
| Vanda Pharmaceuticals Inc. | 14 | $353 |
| Supernus Pharmaceuticals, Inc. | 10 | $264 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $229 |
| Lundbeck LLC | 9 | $172 |
| Alkermes, Inc. | 8 | $151 |
| Bausch Health US, LLC | 7 | $121 |
| Tris Pharma Inc | 4 | $94 |
| Medtronic | 3 | $69 |
| Ironshore Pharmaceuticals Inc. | 3 | $59 |
| Inspire Medical Systems, Inc. | 3 | $49 |
| Jazz Pharmaceuticals Inc. | 3 | $48 |
| Amarin Pharma, Inc. | 3 | $41 |
| Biogen | 2 | $36 |
| Idorsia Pharmaceuticals US Inc | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Genentech USA, Inc. | 2 | $23 |
| Pear Therapeutics (US), Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| Indivior Inc. | 1 | $19 |
| Tempus AI, Inc | 1 | $19 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| Adlon Therapeutics L.p. | 1 | $17 |
| Stryker | 1 | $17 |
| Noven Therapeutics, LLC | 1 | $15 |
| Acadia Pharmaceuticals Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,453 in reported general payments places this provider in the 95th percentile of 231 psychiatry providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 15 | $127,317 |
| Austedo XrDeutetrabenazine | 12 | $74,411 |
| NuplazidPimavanserin Tartrate | 13 | $64,690 |
| SpravatoEsketamine Hcl | 24 | $31,628 |
| VraylarCariprazine Hcl | 12 | $27,273 |
| AuvelityDextromethorphan Hbr/Bupropion | 11 | $11,732 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 40 | $6,594 |
| Buspirone Hcl | 101 | $3,470 |
| Divalproex Sodium ErDivalproex Sodium | 17 | $3,150 |
| Quetiapine Fumarate | 96 | $2,682 |
| Atomoxetine Hcl | 19 | $2,156 |
| Duloxetine Hcl | 76 | $2,106 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 18 | $2,036 |
| Bupropion XlBupropion Hcl | 50 | $1,791 |
| Aripiprazole | 58 | $1,642 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $476 | $127,31715 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $398 | $74,41112 claims |
| Acadia Pharmaceuticals IncNuplazid | $13 | $64,69013 claims |
| Johnson & JohnsonSpravato | $1,134 | $31,62824 claims |
| AbbVieVraylar | $1,128 | $27,27312 claims |
| Axsome Therapeutics, Inc.Auvelity | $570 | $11,73211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 231 psychiatry providers in Utah.
Other psychiatry in Layton
- Julie WieseLayton$4K
- Julana SchenkLayton$1K
- Anthony VitaLayton$823
- Michael MeasomSlc$2.2M
- Noel GardnerSalt Lake City$512K
- Reid RobisonOrem$133K
- Thomas RaynerProvo$60K
- Trent HolmbergDraper$32K
- Nathan CurrierRiverton$21K
- Oliver McPhersonBountiful$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.